Sequoia China led the investment, and Weike Medical completed hundreds of millions of yuan of Series B financing

[Lieyun Network (WeChat: ilieyun) Beijing] reported on December 16

Recently, Weike Medical, a minimally invasive interventional medical device innovator with structural heart disease, announced the completion of hundreds of millions of yuan of B round financing, which was led by Sequoia China, and the original shareholder Sheng Yu Investment continued to support.

It is understood that this round of funds will be mainly used to promote the research and development and innovation of a variety of minimally invasive interventional products of the company, accelerate the process of product registration and listing, and bring better treatment solutions to the majority of structural heart disease patients in China as soon as possible.

Dr. Shang Xiaoke, Chairman of Weike Medical, said: "Thanks to the recognition of many leading professional investment institutions for Weike Medical, our core concept is to develop the first structural heart disease innovation device with independent intellectual property rights in China to benefit more patients. After more than three years of continuous cultivation, Weike Medical has become synonymous with domestic minimally invasive interventional treatment devices for heart failure, and in the next few years, the company will continue to lay out cutting-edge products in science and technology around the field of structural heart disease heart failure. Whether it is China's first D-shant shunt or the world's leading differentiated interventional valve, Weike Medical represents the accurate judgment of China's top professional clinical front-line surgeon team, aiming at the difficulties and pain points that have not yet been solved clinically, and is committed to filling the gap in the market, which is the difference between Weike Medical and many medical companies. On the other hand, the company's rapid development is inseparable from the full help of two professional partners, as well as the full support of the shareholders of the capital, we are confident to maintain a high-speed development trend in this field, accelerate the layout of innovative device research and development and product clinical registration progress, and live up to everyone's expectations. ”

Ms. Yang Yunxia, Partner of Sequoia China, said: "We very much recognize the vision and execution of the Weike team in selecting products: the significance of the atrial shunt for the treatment of heart failure is being accepted by more and more experts around the world, and TAVR for aortic regurgitation is also a product suitable for the epidemiological characteristics of aortic valve disease in China, and Weike is one of the pioneers in these fields. Sequoia China has been committed to helping innovative medical device companies grow rapidly in order to make better products benefit patients faster, and the field of structural heart disease, including heart failure, valvular disease, and congenital heart disease, is one of our key tracks. ”

Founded in 2018, Vicker Medical focuses on product innovation in the field of minimally invasive interventions in structural heart disease. After 3 years of rapid development, the company has focused on the three subdivisions of heart failure, congenital heart disease and valvular heart disease in the field of structural heart disease, and has led the research and development of a number of domestic first and world-leading minimally invasive interventional product pipelines. Among them, the nano membrane oval hole unclosed occlusion device has completed clinical enrollment, the D-shant atrial shunt has entered the multi-center clinical research stage, and the percutaneous transcatheter aortic valve replacement system originally designed for simple aortic valve reflux will enter the clinic in the near future, in addition, the innovative design of the heart failure treatment device series has formed a layout, and some devices will enter the clinic in 2022.

Weike Medical has a medical-engineering R & D team, different from most medical innovation enterprises, is led by a large number of domestic top structural cardiologists to participate in research and development, adhering to the concept of "clinician source innovation", truly pay attention to major clinical treatment needs, keep up with the frontier direction of international disciplines, and is committed to creating medical value from innovative device research and development.